|
|
|
| Clinical Value of HRCT Combined with Pulmonary Function Examination in the Diagnosis of Connective Tissue Disease-Related Pulmonary Interstitial Lesions |
| LIANG Zhiqiang, JIANG Fengyun, ZHAO Lei, et al |
| The Affiliated Hospital of Chengde Medical College, Hebei Chengde 067000, China |
|
|
|
|
Abstract Objective: To investigate the clinical value of HRCT combined with pulmonary function test in the diagnosis of connective tissue disease associated with interstitial lung disease (CTD-ILD). Methods: CTD-ILD was performed in 42 CTD-ILD patients from Jan. 2015 to Dec. 2015. CTD-ILD was performed in 33 patients with CTD alone, and CTD was performed in healthy subjects at the same time. Thirty cases were taken as control group. All the patients were scanned by high resolution CT (HRCT) and lung function was examined. The lung function of the three groups was compared and the application of pulmonary function test in the diagnosis of CTD-ILD was analyzed. Results: Compared with CTD group and control group, the total lung CTD-ILD group (TLC), forced vital capacity (FVC), forced expiratory volume (FEV1) were significant differences (P < 0.05); the CTD group and the control group had no significant difference compared to the lung function index. Among the 42 patients with CTD-ILD, 30 cases were detected by HRCT, the detection rate was 71.4%, and 12 cases of HRCT were not detected in 11 patients The combined detection rate was 97.6%, and the detection rate of HRCT was significantly higher than that of HRCT, the difference was statistically significant (P<0.05). Conclusion: HRCT combined with pulmonary function test for the diagnosis of connective tissue disease-related interstitial lung disease can effectively improve the detection rate, connective tissue disease patients with pulConmonary function suggest that pulmonary interstitial lesions may occur, it should cause clinical attention
|
|
|
|
|
|
[1] Wells AV, Denton CP. Interstitial lung disease in connective tissue disease-mechanisms and management [J]. Nat Rev Rheumatol,2014,49(10): 728~739.
[2] Gutsche M, Rosen GD, Swigris JJ. Connective tissue diseaseassociated interstitial lung disease: a review[J].Curr Respir Care Rep,2012,1(4): 224~232.
[3] De Lauretis A,Veeraraghavan S,Renzoni E. Review series: aspects of interstitial lung disease: connective tissue disease-associated interstitial lung disease: how does it differ from IPF? How should the clinical approach differ[J]. Chron Respir Dis,2011,8 (1) : 53~82.
[4] 李艳,芦运生,郭濴,等.高分辨率CT在结缔组织病所致肺间质病变诊断中的作用[J].中华实用诊断与治疗杂志,2011,25(12):1214~1215.
[5] Elhai M,Meune C,Avouac J,et al. Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies[J].Rheumatology ( Oxford) ,2011,37( 1) : 50~58.
[6] Hamaguchi Y. Autoantibody profiles in systemic sclerosis: predictive value for clinical evaluation and prognosis[J].Dermatol,2010,37( 1) : 42~53.
[7] Domiciano DS,Bonfá E,Borges CT,et al. A long -term prospective randomized controlled study of non-specific interstitial pneumonia( NSIP) treatment in scleroderma[J].Clin Rheumatol,2011,30(2) : 223~229.
[8] 王丽娟,杨旭燕,汪慧英.结缔组织病肺间质病变的诊治进展[J].细胞与分子免疫学杂志,2011,27(1):115~117.
[9] Schnabel A,Reuter M,Biederer JRC,et al. Interstitial lung disease in polymyositis and dermatomyositis: clinical course and response to treatment[J].Semin Arthritis Rheum,2013,32( 5) :273~284. |
| [1] |
. [J]. 河北医学, 2017, 23(8): 1345-1347. |
|
|
|
|
2017, Vol. 23 
